医学
骨关节炎
药品
药物输送
关节软骨
药物开发
药理学
疾病
合成代谢
重症监护医学
生物信息学
内科学
病理
生物
替代医学
化学
有机化学
作者
Huirong Huang,Yujie Lin,Yiling Jiang,Qing Yao,Ruijie Chen,Ying‐Zheng Zhao,Longfa Kou
标识
DOI:10.1016/j.ejpb.2022.12.012
摘要
Osteoarthritis (OA) is the most prevalent chronic degenerative joint disease. It weakens the motor function of patients and imposes a significant economic burden on society. The current medications commonly used in clinical practice do not meet the need for the treatment of OA. Recombinant protein drugs (RPDs) can treat OA by inhibiting inflammatory pathways, regulating catabolism/anabolism, and promoting cartilage repair, thereby showing promise as disease-modifying OA drugs (DMOADs). However, the rapid clearance and short half-life of them in the articular cavity limit their clinical translation. Therefore, the reliable drug delivery systems for extending drug treatment are necessary for the further development. This review introduces RPDs with therapeutic potential for OA, and summarizes their research progress on related drug delivery systems, and make proper discussion on the certain keys for optimal development of this area.
科研通智能强力驱动
Strongly Powered by AbleSci AI